2X 121

Drug Profile

2X 121

Alternative Names: 2X-121; E-7449

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Developer 2X Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors; Tankyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported B cell lymphoma

Most Recent Events

  • 12 Oct 2017 Phase-I/II development for Solid tumours is ongoing in United Kingdom (PO) (2X Oncology pipeline, October 2017)
  • 12 Oct 2017 No recent reports on development identified - Phase-I/II for B-cell lymphoma in United Kingdom (PO)
  • 12 Oct 2017 2X Oncology plans phase II trials for Ovarian cancer (recurrent), and Pancreatic cancer in USA (PO) (2X Oncology website, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top